These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 2299192)
1. Antigen dynamics in melanocytic and nevocytic melanoma oncogenesis: anti-ganglioside and anti-ras p21 antibodies as markers of tumor progression. Yamamura K; Mishima Y J Invest Dermatol; 1990 Feb; 94(2):174-82. PubMed ID: 2299192 [TBL] [Abstract][Full Text] [Related]
2. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. Nores GA; Dohi T; Taniguchi M; Hakomori S J Immunol; 1987 Nov; 139(9):3171-6. PubMed ID: 3668254 [TBL] [Abstract][Full Text] [Related]
3. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. Pukel CS; Lloyd KO; Travassos LR; Dippold WG; Oettgen HF; Old LJ J Exp Med; 1982 Apr; 155(4):1133-47. PubMed ID: 7061953 [TBL] [Abstract][Full Text] [Related]
4. Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma. Hersey P Cancer Treat Res; 1991; 54():137-51. PubMed ID: 1673856 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of melanoma-associated gangliosides in cancer patients. Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Natali PG; Bigotti A; Nicotra MR; Nardi RM; Delovu A; Segatto O; Ferrone S Cancer Res; 1989 Mar; 49(5):1269-74. PubMed ID: 2917356 [TBL] [Abstract][Full Text] [Related]
7. Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Berd D; Herlyn M; Koprowski H; Mastrangelo MJ Cancer Res; 1989 Dec; 49(23):6840-4. PubMed ID: 2582430 [TBL] [Abstract][Full Text] [Related]
8. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711 [TBL] [Abstract][Full Text] [Related]
9. Ganglioside profiles of experimental melanomas and of their melanosomal fractions. Vedralová E; Borovanský J; Hach P Melanoma Res; 1995 Apr; 5(2):87-92. PubMed ID: 7620344 [TBL] [Abstract][Full Text] [Related]
10. Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides. Abdel-Wahab Z; Li WP; Darrow T; Nudelman ED; Towell A; Seigler HF Melanoma Res; 1993 Dec; 3(6):415-23. PubMed ID: 8161881 [TBL] [Abstract][Full Text] [Related]
11. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024 [TBL] [Abstract][Full Text] [Related]
12. Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions. Nakakuma H; Horikawa K; Kawaguchi T; Hidaka M; Nagakura S; Hirai S; Kageshita T; Ono T; Kagimoto T; Iwamori M Jpn J Clin Oncol; 1992 Oct; 22(5):308-12. PubMed ID: 1469793 [TBL] [Abstract][Full Text] [Related]
13. Immunorecognition of ganglioside epitopes: correlation between affinity and cytotoxicity of ganglioside antibodies. Dippold W; Bernhard H Eur J Cancer; 1992; 28A(10):1605-10. PubMed ID: 1382491 [TBL] [Abstract][Full Text] [Related]
14. Human monoclonal antibody to tumor-associated ganglioside GD2: suppressed growth of human melanoma in nude mice. Katano M; Irie RF Immunol Lett; 1984; 8(4):169-74. PubMed ID: 6542067 [TBL] [Abstract][Full Text] [Related]
15. Immunoreactivity of leukemic lymphoblasts of T-cell and B-cell precursor origin with monoclonal anti-GD3 and anti-GM3 antibodies. Merritt WD; Sztein MB; Taylor B; Reaman GH Leukemia; 1991 Dec; 5(12):1087-91. PubMed ID: 1774957 [TBL] [Abstract][Full Text] [Related]
16. The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process. Furukawa K; Thampoe IJ; Yamaguchi H; Lloyd KO J Immunol; 1989 Feb; 142(3):848-54. PubMed ID: 2464027 [TBL] [Abstract][Full Text] [Related]
17. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Taramelli D; Fossati G; Mazzocchi A; Delia D; Ferrone S; Parmiani G Cancer Res; 1986 Jan; 46(1):433-9. PubMed ID: 3079589 [TBL] [Abstract][Full Text] [Related]
18. Surface antigenic profile of uveal melanoma lesions analysed with a panel of monoclonal antibodies directed against cutaneous melanoma. Carrel S; Schreyer M; Gross N; Zografos L Anticancer Res; 1990; 10(1):81-9. PubMed ID: 1692197 [TBL] [Abstract][Full Text] [Related]
19. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1. Nakanishi T; Hashimoto K Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436 [TBL] [Abstract][Full Text] [Related]
20. Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma. Hersey P; Jamal O; Henderson C; Zardawi I; D'Alessandro G Int J Cancer; 1988 Mar; 41(3):336-43. PubMed ID: 3346097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]